-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Healthcare -X- _ O
workers -X- _ O
may -X- _ O
be -X- _ O
exposed -X- _ O
to -X- _ O
people -X- _ O
with -X- _ O
respiratory -X- _ O
viral -X- _ O
infections -X- _ O
more -X- _ O
often -X- _ O
than -X- _ O
other -X- _ O
working -X- _ O
adults. -X- _ O
Understanding -X- _ O
the -X- _ O
risk -X- _ O
and -X- _ O
the -X- _ O
effectiveness -X- _ O
of -X- _ O
different -X- _ O
preventive -X- _ O
measures -X- _ O
is -X- _ O
of -X- _ O
great -X- _ O
importance. -X- _ O
OBJECTIVES -X- _ O
: -X- _ O
To -X- _ O
estimate -X- _ O
adherence -X- _ O
to -X- _ O
prophylactic -X- _ O
antiviral -X- _ O
medication -X- _ O
for -X- _ O
a -X- _ O
full -X- _ O
influenza -X- _ O
season -X- _ O
, -X- _ O
to -X- _ O
the -X- _ O
compare -X- _ O
efficacy -X- _ O
of -X- _ O
antiviral -X- _ B-Intervention
prophylaxis -X- _ I-Intervention
to -X- _ O
that -X- _ O
of -X- _ O
the -X- _ O
seasonal -X- _ B-Comparison
influenza -X- _ I-Comparison
vaccine -X- _ I-Comparison
and -X- _ O
to -X- _ O
identify -X- _ O
exposures -X- _ O
that -X- _ O
increase -X- _ O
risk -X- _ O
of -X- _ O
acute -X- _ O
respiratory -X- _ O
illnesses -X- _ O
( -X- _ O
ARI -X- _ O
) -X- _ O
in -X- _ O
healthy -X- _ O
adults. -X- _ O
METHODS -X- _ O
: -X- _ O
Participants -X- _ B-Comparison
were -X- _ I-Comparison
randomized -X- _ I-Comparison
1:2 -X- _ I-Comparison
to -X- _ I-Comparison
receive -X- _ I-Comparison
the -X- _ I-Comparison
2008–2009 -X- _ I-Comparison
influenza -X- _ I-Comparison
vaccine -X- _ I-Comparison
or -X- _ O
daily -X- _ B-Intervention
prophylaxis -X- _ I-Intervention
with -X- _ I-Intervention
10 -X- _ I-Intervention
mg -X- _ I-Intervention
of -X- _ I-Intervention
zanamivir -X- _ I-Intervention
during -X- _ O
the -X- _ O
season. -X- _ O
Web-based -X- _ O
questionnaires -X- _ O
collected -X- _ O
information -X- _ O
on -X- _ O
demographics -X- _ O
, -X- _ O
symptoms -X- _ O
, -X- _ O
exposures -X- _ O
, -X- _ O
medication -X- _ O
use -X- _ O
and -X- _ O
side -X- _ O
effects. -X- _ O
RESULTS -X- _ O
: -X- _ O
Sixty-four -X- _ B-Patient
healthy -X- _ I-Patient
adults -X- _ I-Patient
were -X- _ O
recruited -X- _ O
in -X- _ O
November -X- _ O
2008. -X- _ O
Three -X- _ O
of -X- _ O
40 -X- _ O
active -X- _ O
participants -X- _ O
discontinued -X- _ O
zanamivir -X- _ O
due -X- _ O
to -X- _ O
side -X- _ O
effects -X- _ O
; -X- _ O
the -X- _ O
remaining -X- _ O
37 -X- _ O
took -X- _ O
> -X- _ O
85 -X- _ O
% -X- _ O
of -X- _ O
scheduled -X- _ O
doses -X- _ O
for -X- _ O
a -X- _ O
median -X- _ O
of -X- _ O
121 -X- _ O
days. -X- _ O
Symptomatic -X- _ B-Outcome
, -X- _ I-Outcome
laboratory- -X- _ I-Outcome
confirmed -X- _ I-Outcome
influenza -X- _ I-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
one -X- _ I-Outcome
person -X- _ I-Outcome
randomized -X- _ I-Outcome
to -X- _ I-Outcome
zanamivir -X- _ I-Outcome
( -X- _ I-Outcome
2·5 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
2 -X- _ I-Outcome
/ -X- _ I-Outcome
20 -X- _ I-Outcome
( -X- _ I-Outcome
10 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
who -X- _ I-Outcome
received -X- _ I-Outcome
the -X- _ I-Outcome
vaccine -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0·25 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Forty-seven -X- _ I-Outcome
participants -X- _ I-Outcome
reported -X- _ I-Outcome
109 -X- _ I-Outcome
episodes -X- _ I-Outcome
of -X- _ I-Outcome
ARI. -X- _ I-Outcome
Factors -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
an -X- _ I-Outcome
ARI -X- _ I-Outcome
were -X- _ I-Outcome
exposure -X- _ I-Outcome
to -X- _ I-Outcome
a -X- _ I-Outcome
spouse -X- _ I-Outcome
( -X- _ I-Outcome
OR -X- _ I-Outcome
7·2 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
child -X- _ I-Outcome
( -X- _ I-Outcome
OR -X- _ I-Outcome
2·4 -X- _ I-Outcome
) -X- _ I-Outcome
or -X- _ I-Outcome
patient -X- _ I-Outcome
( -X- _ I-Outcome
OR -X- _ I-Outcome
2·0 -X- _ I-Outcome
) -X- _ I-Outcome
with -X- _ I-Outcome
symptoms -X- _ I-Outcome
of -X- _ I-Outcome
an -X- _ I-Outcome
ARI -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
previous -X- _ I-Outcome
7 -X- _ I-Outcome
days. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Breakthrough -X- _ B-Outcome
influenza -X- _ I-Outcome
infection -X- _ I-Outcome
occurred -X- _ I-Outcome
in -X- _ I-Outcome
both -X- _ I-Outcome
vaccinated -X- _ I-Outcome
participants -X- _ I-Outcome
and -X- _ I-Outcome
those -X- _ I-Outcome
receiving -X- _ I-Outcome
antiviral -X- _ I-Outcome
prophylaxis. -X- _ I-Outcome
Most -X- _ O
adults -X- _ O
were -X- _ O
willing -X- _ O
and -X- _ O
able -X- _ O
to -X- _ O
comply -X- _ O
with -X- _ O
season-long -X- _ O
prophylaxis. -X- _ O
Report -X- _ O
of -X- _ O
recent -X- _ O
exposure -X- _ O
to -X- _ O
family -X- _ O
members -X- _ O
and -X- _ O
patients -X- _ O
with -X- _ O
an -X- _ O
ARI -X- _ O
increased -X- _ O
the -X- _ O
risk -X- _ O
of -X- _ O
developing -X- _ O
an -X- _ O
ARI -X- _ O
in -X- _ O
healthy -X- _ O
adults -X- _ O
. -X- _ O

